MedTrace Logo

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

NCT00656799 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-03-10

Study results available
· View outcomes & findings →

Summary

The clinical trial objectives were to evaluate the dialysability of the sugammadex-rocuronium complex; it's safety and efficacy in participants with severe renal impairment.

Conditions

  • Neuromuscular Blockade

Interventions

DRUG

sugammadex

At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.

DRUG

Rocuronium

After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00656799 on ClinicalTrials.gov